Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The MLH1 c.1852_1853delinsGC (p.K618A) variant in colorectal cancer: genetic association study in 18,723 individuals

  • Abulí, Anna
  • Andreu Camps, Montserrat
  • Castellví Bel, Sergi
Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as “variants of uncertain significance”, being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723 individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological characteristics including family history for this neoplasm or Lynch syndrome., This work was supported by COST Action BM1206. Groups 1, 4, 5, 6, 7, 8, 10 and 13 are active members of this consortium. Edinburgh: This work was supported by a Cancer Research UK Programme Grant (C348/A12076) and a Centre Grant from the CORE Charity. Epicolon: SCB is supported by a contract from the Fondo de Investigación Sanitaria (CP 03-0070). JM and CEJ are supported by contracts from the CIBERehd. CIBERehd and CIBERER are funded by the Instituto de Salud Carlos III. This work was supported by grants from the Fondo de Investigación Sanitaria/FEDER (11/00219, 11/00681), Instituto de Salud Carlos III (Acción Transversal de Cáncer), Xunta de Galicia (07PXIB9101209PR), Ministerio de Ciencia e Innovación (SAF2010-19273), Asociación Española contra el Cáncer (Fundación Científica GCB13131592CAST y Junta de Barcelona), Fundació Olga Torres (SCB and CRP) and FP7 CHIBCHA Consortium (SCB and ACar). Kiel: This work was supported by the German Ministry for Education and Research through the German National Genome Research Network (NGFNplus) Colon Cancer Network (CCN). Leiden: This work was supported by the Dutch Cancer Society with grant KWF-UL-2005-3247. Stockholm: The Swedish sample and data resource were funded by the Swedish Cancer Society, the Swedish Scientific Research Council and the Stockholm Cancer Foundation. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals

  • Abulí, Anna
  • Bujanda Fernández de Pierola, Luis
  • Mun, Jenifer
  • Buch, Stephan
  • Schafmayer, Clemens
  • Maiorana, Maria Valeria
  • Veneroni, Silvia
  • Van Wezel, Tom
  • Liu, Tao
  • Westers, Helga
  • Esteban-Jurado, Clara
  • Ocan, Teresa
  • Pique, Josep M.
  • Andreu, Montserrat
  • Jover, Rodrigo
  • Carracedo, Angel
  • Xicola, Rosa
  • Llor, Xavier
  • Castells, Antoni
  • The EPICOLON Consortium
  • Dunlop15, Malcolm
  • Hofstra, Robert
  • Lindblom, Annika
  • Wijnen, Juul
  • Peterlongo, Paolo
  • Hampe, Jochen
  • Ruiz Ponte, Clara
  • Castellví-Bel, Sergi
Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as "variants of uncertain significance'', being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723 individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological characteristics including family history for this neoplasm or Lynch syndrome., This work was supported by COST Action BM1206. Groups 1, 4, 5, 6, 7, 8, 10 and 13 are active members of this consortium. Edinburgh: This work was supported by a Cancer Research UK Programme Grant (C348/A12076) and a Centre Grant from the CORE Charity. Epicolon: SCB is supported by a contract from the Fondo de Investigacion Sanitaria (CP 03-0070). JM and CEJ are supported by contracts from the CIBERehd. CIBERehd and CIBERER are funded by the Instituto de Salud Carlos III. This work was supported by grants from the Fondo de Investigacion Sanitaria/FEDER (11/00219, 11/00681), Instituto de Salud Carlos III (Accion Transversal de Cancer), Xunta de Galicia (07PXIB9101209PR), Ministerio de Ciencia e Innovacion (SAF2010-19273), Asociacion Espanola contra el Cancer (Fundacion Cientifica GCB13131592CAST y Junta de Barcelona), Fundacio Olga Torres (SCB and CRP) and FP7 CHIBCHA Consortium (SCB and ACar). Kiel: This work was supported by the German Ministry for Education and Research through the German National Genome Research Network (NGFNplus) Colon Cancer Network (CCN). Leiden: This work was supported by the Dutch Cancer Society with grant KWF-UL-2005-3247. Stockholm: The Swedish sample and data resource were funded by the Swedish Cancer Society, the Swedish Scientific Research Council and the Stockholm Cancer Foundation. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Association between CASP8 –652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study

  • Pardini, Barbara
  • Verderio, Paolo
  • Pizzamiglio, Sara
  • Nici, Carmela
  • Maiorana, Maria Valeria
  • Naccarati, Alessio
  • Vodickova, Ludmila
  • Vymetalkova, Veronika
  • Veneroni, Silvia
  • Daidone, Maria Grazia
  • Ravagnani, Fernando
  • Bianchi, Tiziana
  • Bujanda, Luis
  • Carracedo, Angel
  • Castells, Antoni
  • Ruiz-Ponte, Clara
  • Morreau, Hans
  • Howarth, Kimberley
  • Jones, Angela
  • Castellví-Bel, Sergi
  • Li, Li
  • Tomlinson, Ian
  • Van Wezel, Tom
  • Vodicka, Pavel
  • Radice, Paolo
  • Peterlongo, Paolo
Members of the EPICOLON Consortium (Gastrointestinal Oncology Group of the Spanish Gastroenterological Association) are: Hospital 12 de Octubre, Madrid: Juan Diego Morillas (local coordinator), Raquel Muñoz, Marisa Manzano, Francisco Colina, Jose Díaz, Carolina Ibarrola, Guadalupe López, Alberto Ibáñez; Hospital Clínic, Barcelona: Antoni Castells (local coordinator), Virgínia Piñol, Sergi Castellví-Bel, Francesc Balaguer, Victoria Gonzalo, Teresa Ocaña, María Dolores Giráldez, Maria Pellisé, Anna Serradesanferm, Leticia Moreira, Miriam Cuatrecasas, Josep M. Piqué; Hospital Clínico Universitario, Zaragoza: Ángel Lanas (local coordinator), Javier Alcedo, Javier Ortego; Hospital Cristal-Piñor, Complexo Hospitalario de Ourense: Joaquin Cubiella (local coordinator), Ma Soledad Díez, Mercedes Salgado, Eloy Sánchez, Mariano Vega; Parc de Salut Mar, Barcelona: Montserrat Andreu (local coordinator), Anna Abuli, Xavier Bessa, Mar Iglesias, Agustín Seoane, Felipe Bory, Gemma Navarro, Beatriz Bellosillo; Josep Ma Dedeu, Cristina Álvarez, Marc Puigvehí; Hospital San Eloy, Baracaldo and Hospital Donostia, CIBERehd, University of Basque Country, San Sebastián: Luis Bujanda (local coordinator) Ángel Cosme, Inés Gil, Mikel Larzabal, Carlos Placer, María del Mar Ramírez, Elisabeth Hijona, Jose M. Enríquez-Navascués, Jose L. Elosegui; Hospital General Universitario de Alicante: Artemio Payá (EPICOLON I local coordinator), Rodrigo Jover (EPICOLON II local coordinator), Cristina Alenda, Laura Sempere, Nuria Acame, Estefanía Rojas, Lucía Pérez-Carbonell; Hospital General de Granollers: Joaquim Rigau (local coordinator), Ángel Serrano, Anna Giménez; Hospital General de Vic: Joan Saló (local coordinator), Eduard Batiste-Alentorn, Josefina Autonell, Ramon Barniol; Hospital General Universitario de Guadalajara and Fundación para la Formación e Investigación Sanitarias Murcia: Ana María García (local coordinator), Fernando Carballo, Antonio Bienvenido, Eduardo Sanz, Fernando González, Jaime Sánchez, Akiko Ono; Hospital General Universitario de Valencia: Mercedes Latorre (local coordinator), Enrique Medina, Jaime Cuquerella, Pilar Canelles, Miguel Martorell, José Ángel García, Francisco Quiles, Elisa Orti; CHUVI-Hospital Meixoeiro, Vigo: EPICOLON I: Juan Clofent (local coordinator), Jaime Seoane, Antoni Tardío, Eugenia Sanchez. EPICOLON II Ma Luisa de Castro (local coordinator), Antoni Tardío, Juan Clofent, Vicent Hernández; Hospital Universitari Germans Trias i Pujol, Badalona and Section of Digestive Diseases and Nutrition, University of Illinois at Chicago, IL, USA: Xavier Llor (local coordinator), Rosa M. Xicola, Marta Piñol, Mercè Rosinach, Anna Roca, Elisenda Pons, José M. Hernández, Miquel A. Gassull; Hospital Universitari Mútua de Terrassa: Fernando Fernández-Bañares (local coordinator), Josep M. Viver, Antonio Salas, Jorge Espinós, Montserrat Forné, Maria Esteve; Hospital Universitari Arnau de Vilanova, Lleida: Josep M. Reñé (local coordinator), Carmen Piñol, Juan Buenestado, Joan Viñas; Hospital Universitario de Canarias: Enrique Quintero (local coordinator), David Nicolás, Adolfo Parra, Antonio Martín; Hospital Universitario La Fe, Valencia: Lidia Argüello (local coordinator), Vicente Pons, Virginia Pertejo, Teresa Sala; Hospital Sant Pau, Barcelona: Dolors Gonzalez (local coordinator) Eva Roman, Teresa Ramon, Maria Poca, Ma Mar Concepción, Marta Martin, Lourdes Pétriz; Hospital Xeral Cies, Vigo: Daniel Martinez (local coordinator); Fundacion Publica Galega de Medicina Xenomica (FPGMX), CIBERER, Genomic Medicine Group-University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain: Ángel Carracedo (local coordinator), Clara Ruiz-Ponte, Ceres Fernández-Rozadilla, Ma Magdalena Castro; Hospital Universitario Central de Asturias: Sabino Riestra (local coordinator), Luis Rodrigo; Hospital de Galdácano, Vizcaya: Javier Fernández (local coordinator), Jose Luis Cabriada; Fundación Hospital de Calahorra (La Rioja) La Rioja: Luis Carreño (local coordinator), Susana Oquiñena, Federico Bolado; Hospital Royo Villanova, Zaragoza: Elena Peña (local coordinator), José Manuel Blas, Gloria Ceña, Juan José Sebastián; Hospital Universitario Reina Sofía, Córdoba: Antonio Naranjo (local coordinator)., The common −652 6N del variant in the CASP8 promoter (rs3834129) has been described as a putative low-penetrance risk factor for different cancer types. In particular, some studies suggested that the deleted allele (del) was inversely associated with CRC risk while other analyses failed to confirm this. Hence, to better understand the role of this variant in the risk of developing CRC, we performed a multi-centric case-control study. In the study, the variant −652 6N del was genotyped in a total of 6,733 CRC cases and 7,576 controls recruited by six different centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands collaborating to the international consortium COGENT (COlorectal cancer GENeTics). Our analysis indicated that rs3834129 was not associated with CRC risk in the full data set. However, the del allele was under-represented in one set of cases with a family history of CRC (per allele model OR = 0.79, 95% CI = 0.69–0.90) suggesting this allele might be a protective factor versus familial CRC. Since this multi-centric case-control study was performed on a very large sample size, it provided robust clarification of the effect of rs3834129 on the risk of developing CRC in Caucasians., For all cohorts: This work was supported by COST Action BM1206. Spanish cohort: SCB is supported by a contract from the Fondo de Investigación Sanitaria (CP 03-0070 to SCB). Networked Biomedical Research Centre for Hepatic and Digestive Diseases and Centro de Investigación Biomédica en Red de Enfermedades Raras are funded by the Instituto de Salud Carlos III. This work was supported by grants from the Fondo de Investigación Sanitaria/FEDER (08/0024, 08/1276, PS09/02368, 11/00219, 11/00681), Instituto de Salud Carlos III (Acción Transversal de Cáncer), Xunta de Galicia (07PXIB9101209PR), Ministerio de Ciencia e Innovación (SAF2010-19273), Asociación Española contra el Cáncer (Fundación Científica y Junta de Barcelona), Fundació Olga Torres (SCB and CRP), FP7 CHIBCHA Consortium (SCB and A. Carracedo). American cohort: Kentucky Colon Cancer Genetic Epidemiology Study is supported by National Institutes of Health grant R01CA136726 to LL. English cohort: Core funding to the Wellcome Trust Centre for Human Genetics was provided by the Wellcome Trust (090532/Z/09/Z). Czech cohort: Grant agency of the Czech Republic (GACR) [CZ:GACR:GA P304/10/1286 and P304/12/1585] and by Prvouk-P27/LF1/1 from Ministry of Education, Youth and Sport, Czech Republic (First Medical Faculty, Charles University, Prague, Czech Republic as a recipient). Dutch cohort: Dutch Cancer Society, grant KWF-UL-2010-4656.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer

  • Castells Garangou, Antoni
  • Castellví Bel, Sergi
  • The COGENT Consortium
  • The CORGI Collaborators
  • The EPICOLON Consortium
Genome-wide association studies (GWAS) have identified 14 tagging single nucleotide polymorphisms (tagSNPs) that are associated with the risk of colorectal cancer (CRC), and several of these tagSNPs are near bone morphogenetic protein (BMP) pathway loci. The penalty of multiple testing implicit in GWAS increases the attraction of complementary approaches for disease gene discovery, including candidate gene- or pathway-based analyses. The strongest candidate loci for additional predisposition SNPs are arguably those already known both to have functional relevance and to be involved in disease risk. To investigate this proposition, we searched for novel CRC susceptibility variants close to the BMP pathway genes GREM1 (15q13.3), BMP4 (14q22.2), and BMP2 (20p12.3) using sample sets totalling 24,910 CRC cases and 26,275 controls. We identified new, independent CRC predisposition SNPs close to BMP4 (rs1957636, P = 3.93×10−10) and BMP2 (rs4813802, P = 4.65×10−11). Near GREM1, we found using fine-mapping that the previously-identified association between tagSNP rs4779584 and CRC actually resulted from two independent signals represented by rs16969681 (P = 5.33×10−8) and rs11632715 (P = 2.30×10−10). As low-penetrance predisposition variants become harder to identify owing to small effect sizes and/or low risk allele frequencies approaches based on informed candidate gene selection may become increasingly attractive. Our data emphasise that genetic fine-mapping studies can deconvolute associations that have arisen owing to independent correlation of a tagSNP with more than one functional SNP, thus explaining some of the apparently missing heritability of common diseases.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer

  • Tomlinson, Ian P.
  • Dunlop, Malcolm
  • Campbell, Harry
  • Zanke, Brent W.
  • Gallinger, Steven
  • Hudson, Thomas J.
  • Koessler, Thibaud
  • Pharoah, Paul D. P.
  • Niittymäki, Iina
  • Tuupanen, Sari
  • Aaltonen, Lauri A.
  • Hemminki, Kari
  • Lindblom, Annika
  • Försti, Asta
  • Sieber, Oliver
  • Lipton, Lara
  • Van Wezel, Tom
  • Morreau, Hans
  • Wijnen, Juul
  • Devilee, Peter
  • Matsuda, Kenji
  • Nakamura, Yusuke
  • Castellví Bel, Sergi
  • Ruiz-Ponte, Clara
  • Castells Garangou, Antoni
  • Carracedo Álvarez, Ángel
  • Ho, J.W.
  • Sham, Pak Chung
  • Hofstra, Robert
  • Vodicka, Pavel
  • Brenner, Hermann
  • Hampe, Jochen
  • Schafmayer, Clemens
  • Tepel, Juergen
  • Schreiber, Stefan
  • Völzke, Henry
  • Lerch, Markus M.
  • Schmidt, Christian A.
  • Buch, Stephan
  • Moreno Aguado, Víctor
It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The MLH1 c.1852_1853delinsGC (p.K618A) variant in colorectal cancer: genetic association study in 18,723 individuals.

  • Abulí, Anna
  • Bujanda, Luis
  • Muñoz, Jenifer
  • Buch, Stephan
  • Schafmayer, Clemens
  • Maiorana, Maria Valeria
  • Veneroni, Silvia
  • Van Wezel, Tom
  • Liu, Tao
  • Westers, Helga
  • Esteban-Jurado, Clara
  • Ocaña, Teresa
  • Piqué, J. M. (Piqué Badía)
  • Andreu, Montserrat
  • Jover, Rodrigo
  • Carracedo Álvarez, Ángel
  • Llor, Xavier
  • Castells Garangou, Antoni
  • Dunlop, Malcolm
  • Hofstra, Robert
  • Lindblom, Annika
  • Xicola, Rosa
  • Wijnen, Juul
  • Peterlongo, Paolo
  • Hampe, Jochen
  • Ruiz-Ponte, Clara
  • Castellví Bel, Sergi
Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as "variants of uncertain significance", being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723 individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological characteristics including family history for this neoplasm or Lynch syndrome.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Development of a panel of genome-wide ancestry informative markers to study admixture throughout the Americas

  • Galanter, Joshua
  • Fernandez, Juan Carlos
  • Gignoux, Christopher R.
  • Barnholtz-Sloan, Jill
  • Fernandez, Ceres
  • Via i García, Marc
  • Hidalgo-Miranda, Alfredo
  • Contreras, Alejandra V.
  • Uribe Figueroa, Laura
  • Raska, Paola
  • Jiménez-Sánchez, Gerardo
  • Silva Zolezzi, Irma
  • Torres, Maria
  • Ruiz-Ponte, Clara
  • Ruiz, Yarimar
  • Salas, Antonio
  • Nguyen, Elizabeth
  • Eng, Celeste
  • Borjas, Lisbeth
  • Zabala, William
  • Barreto, Guillermo
  • Rondón, Fernando
  • Ibarra, Adriana
  • Taboada, Patricia
  • Porras, Liliana
  • Moreno, Fabián
  • Bigham, Abigail
  • Gutierrez, Gerardo
  • Brutsaert, Tom
  • León-Velarde, Fabiola
  • Moore, Lorna G.
  • Vargas, Enrique
  • Cruz, Miguel
  • Escobedo, Jorge
  • Rodriguez-Santana, José
  • Rodriguez-Cintron, William
  • Chapela, Rocio
  • Ford, Jean G.
  • Bustamante, Carlos D.
  • LACE Consortium
Most individuals throughout the Americas are admixed descendants of Native American, European, and African ancestors. Complex historical factors have resulted in varying proportions of ancestral contributions between individuals within and among ethnic groups. We developed a panel of 446 ancestry informative markers (AIMs) optimized to estimate ancestral proportions in individuals and populations throughout Latin America. We used genome-wide data from 953 individuals from diverse African, European, and Native American populations to select AIMs optimized for each of the three main continental populations that form the basis of modern Latin American populations. We selected markers on the basis of locus-specific branch length to be informative, well distributed throughout the genome, capable of being genotyped on widely available commercial platforms, and applicable throughout the Americas by minimizing within-continent heterogeneity. We then validated the panel in samples from four admixed populations by comparing ancestry estimates based on the AIMs panel to estimates based on genome-wide association study (GWAS) data. The panel provided balanced discriminatory power among the three ancestral populations and accurate estimates of individual ancestry proportions (R2>0.9 for ancestral components with significant between-subject variance). Finally, we genotyped samples from 18 populations from Latin America using the AIMs panel and estimated variability in ancestry within and between these populations. This panel and its reference genotype information will be useful resources to explore population history of admixture in Latin America and to correct for the potential effects of population stratification in admixed samples in the region.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Association between CASP8-652 6N del polymorphism (rs3834129) and colorectal cancer risk: results from a multi-centric study

  • Pardini, Barbara
  • Verderio, Paolo
  • Pizzamiglio, Sara
  • Nici, Carmela
  • Maiorana, Maria Valeria
  • Naccarati, Alessio
  • Vodickova, Ludmila
  • Vymetalkova, Veronika
  • Veneroni, Silvia
  • Daidone, Maria Grazia
  • Ravagnani, Fernando
  • Bianchi, Tiziana
  • Bujanda, Luis
  • Carracedo, Arkaitz
  • Castells Garangou, Antoni
  • Ruiz-Ponte, Clara
  • Morreau, Hans
  • Howarth, Kimberley
  • Jones, Angela
  • Castellví Bel, Sergi
  • Li, Li
  • Tomlinson, Ian P.
  • Van Wezel, Tom
  • Vodicka, Pavel
  • Radice, Paolo
  • Peterlongo, Paolo
The common −652 6N del variant in the CASP8 promoter (rs3834129) has been described as a putative low-penetrance risk factor for different cancer types. In particular, some studies suggested that the deleted allele (del) was inversely associated with CRC risk while other analyses failed to confirm this. Hence, to better understand the role of this variant in the risk of developing CRC, we performed a multi-centric case-control study. In the study, the variant −652 6N del was genotyped in a total of 6,733 CRC cases and 7,576 controls recruited by six different centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands collaborating to the international consortium COGENT (COlorectal cancer GENeTics). Our analysis indicated that rs3834129 was not associated with CRC risk in the full data set. However, the del allele was under-represented in one set of cases with a family history of CRC (per allele model OR = 0.79, 95% CI = 0.69-0.90) suggesting this allele might be a protective factor versus familial CRC. Since this multi-centric case-control study was performed on a very large sample size, it provided robust clarification of the effect of rs3834129 on the risk of developing CRC in Caucasians.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The MLH1 c.1852_1853delinsGC (p.K618A) variant in colorectal cancer: genetic association study in 18,723 individuals.

  • Abulí, Anna
  • Bujanda, Luis
  • Muñoz, Jenifer
  • Buch, Stephan
  • Schafmayer, Clemens
  • Maiorana, Maria Valeria
  • Veneroni, Silvia
  • Van Wezel, Tom
  • Liu, Tao
  • Westers, Helga
  • Esteban-Jurado, Clara
  • Ocaña, Teresa
  • Piqué, J. M. (Piqué Badía)
  • Andreu, Montserrat
  • Jover, Rodrigo
  • Carracedo Álvarez, Ángel
  • Llor, Xavier
  • Castells Garangou, Antoni
  • Dunlop, Malcolm
  • Hofstra, Robert
  • Lindblom, Annika
  • Xicola, Rosa
  • Wijnen, Juul
  • Peterlongo, Paolo
  • Hampe, Jochen
  • Ruiz-Ponte, Clara
  • Castellví Bel, Sergi
Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as "variants of uncertain significance", being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723 individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological characteristics including family history for this neoplasm or Lynch syndrome.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer

  • Castells Garangou, Antoni
  • Castellví Bel, Sergi
  • The COGENT Consortium
  • The CORGI Collaborators
  • The EPICOLON Consortium
Genome-wide association studies (GWAS) have identified 14 tagging single nucleotide polymorphisms (tagSNPs) that are associated with the risk of colorectal cancer (CRC), and several of these tagSNPs are near bone morphogenetic protein (BMP) pathway loci. The penalty of multiple testing implicit in GWAS increases the attraction of complementary approaches for disease gene discovery, including candidate gene- or pathway-based analyses. The strongest candidate loci for additional predisposition SNPs are arguably those already known both to have functional relevance and to be involved in disease risk. To investigate this proposition, we searched for novel CRC susceptibility variants close to the BMP pathway genes GREM1 (15q13.3), BMP4 (14q22.2), and BMP2 (20p12.3) using sample sets totalling 24,910 CRC cases and 26,275 controls. We identified new, independent CRC predisposition SNPs close to BMP4 (rs1957636, P = 3.93×10−10) and BMP2 (rs4813802, P = 4.65×10−11). Near GREM1, we found using fine-mapping that the previously-identified association between tagSNP rs4779584 and CRC actually resulted from two independent signals represented by rs16969681 (P = 5.33×10−8) and rs11632715 (P = 2.30×10−10). As low-penetrance predisposition variants become harder to identify owing to small effect sizes and/or low risk allele frequencies approaches based on informed candidate gene selection may become increasingly attractive. Our data emphasise that genetic fine-mapping studies can deconvolute associations that have arisen owing to independent correlation of a tagSNP with more than one functional SNP, thus explaining some of the apparently missing heritability of common diseases.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The MLH1 c.1852_1853delinsGC (p.K618A) variant in colorectal cancer: genetic association study in 18,723 individuals

  • Abulí, Anna
  • Andreu Camps, Montserrat
  • Castellví Bel, Sergi
Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as “variants of uncertain significance”, being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723 individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological characteristics including family history for this neoplasm or Lynch syndrome., This work was supported by COST Action BM1206. Groups 1, 4, 5, 6, 7, 8, 10 and 13 are active members of this consortium. Edinburgh: This work was supported by a Cancer Research UK Programme Grant (C348/A12076) and a Centre Grant from the CORE Charity. Epicolon: SCB is supported by a contract from the Fondo de Investigación Sanitaria (CP 03-0070). JM and CEJ are supported by contracts from the CIBERehd. CIBERehd and CIBERER are funded by the Instituto de Salud Carlos III. This work was supported by grants from the Fondo de Investigación Sanitaria/FEDER (11/00219, 11/00681), Instituto de Salud Carlos III (Acción Transversal de Cáncer), Xunta de Galicia (07PXIB9101209PR), Ministerio de Ciencia e Innovación (SAF2010-19273), Asociación Española contra el Cáncer (Fundación Científica GCB13131592CAST y Junta de Barcelona), Fundació Olga Torres (SCB and CRP) and FP7 CHIBCHA Consortium (SCB and ACar). Kiel: This work was supported by the German Ministry for Education and Research through the German National Genome Research Network (NGFNplus) Colon Cancer Network (CCN). Leiden: This work was supported by the Dutch Cancer Society with grant KWF-UL-2005-3247. Stockholm: The Swedish sample and data resource were funded by the Swedish Cancer Society, the Swedish Scientific Research Council and the Stockholm Cancer Foundation. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association between CASP8-652 6N del polymorphism (rs3834129) and colorectal cancer risk: results from a multi-centric study

  • Pardini, Barbara
  • Verderio, Paolo
  • Pizzamiglio, Sara
  • Nici, Carmela
  • Maiorana, Maria Valeria
  • Naccarati, Alessio
  • Vodickova, Ludmila
  • Vymetalkova, Veronika
  • Veneroni, Silvia
  • Daidone, Maria Grazia
  • Ravagnani, Fernando
  • Bianchi, Tiziana
  • Bujanda, Luis
  • Carracedo, Arkaitz
  • Castells Garangou, Antoni
  • Ruiz-Ponte, Clara
  • Morreau, Hans
  • Howarth, Kimberley
  • Jones, Angela
  • Castellví Bel, Sergi
  • Li, Li
  • Tomlinson, Ian P.
  • Van Wezel, Tom
  • Vodicka, Pavel
  • Radice, Paolo
  • Peterlongo, Paolo
The common −652 6N del variant in the CASP8 promoter (rs3834129) has been described as a putative low-penetrance risk factor for different cancer types. In particular, some studies suggested that the deleted allele (del) was inversely associated with CRC risk while other analyses failed to confirm this. Hence, to better understand the role of this variant in the risk of developing CRC, we performed a multi-centric case-control study. In the study, the variant −652 6N del was genotyped in a total of 6,733 CRC cases and 7,576 controls recruited by six different centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands collaborating to the international consortium COGENT (COlorectal cancer GENeTics). Our analysis indicated that rs3834129 was not associated with CRC risk in the full data set. However, the del allele was under-represented in one set of cases with a family history of CRC (per allele model OR = 0.79, 95% CI = 0.69-0.90) suggesting this allele might be a protective factor versus familial CRC. Since this multi-centric case-control study was performed on a very large sample size, it provided robust clarification of the effect of rs3834129 on the risk of developing CRC in Caucasians.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Development of a panel of genome-wide ancestry informative markers to study admixture throughout the Americas

  • Galanter, Joshua
  • Fernandez, Juan Carlos
  • Gignoux, Christopher R.
  • Barnholtz-Sloan, Jill
  • Fernandez, Ceres
  • Via i García, Marc
  • Hidalgo-Miranda, Alfredo
  • Contreras, Alejandra V.
  • Uribe Figueroa, Laura
  • Raska, Paola
  • Jiménez-Sánchez, Gerardo
  • Silva Zolezzi, Irma
  • Torres, Maria
  • Ruiz-Ponte, Clara
  • Ruiz, Yarimar
  • Salas, Antonio
  • Nguyen, Elizabeth
  • Eng, Celeste
  • Borjas, Lisbeth
  • Zabala, William
  • Barreto, Guillermo
  • Rondón, Fernando
  • Ibarra, Adriana
  • Taboada, Patricia
  • Porras, Liliana
  • Moreno, Fabián
  • Bigham, Abigail
  • Gutierrez, Gerardo
  • Brutsaert, Tom
  • León-Velarde, Fabiola
  • Moore, Lorna G.
  • Vargas, Enrique
  • Cruz, Miguel
  • Escobedo, Jorge
  • Rodriguez-Santana, José
  • Rodriguez-Cintron, William
  • Chapela, Rocio
  • Ford, Jean G.
  • Bustamante, Carlos D.
  • LACE Consortium
Most individuals throughout the Americas are admixed descendants of Native American, European, and African ancestors. Complex historical factors have resulted in varying proportions of ancestral contributions between individuals within and among ethnic groups. We developed a panel of 446 ancestry informative markers (AIMs) optimized to estimate ancestral proportions in individuals and populations throughout Latin America. We used genome-wide data from 953 individuals from diverse African, European, and Native American populations to select AIMs optimized for each of the three main continental populations that form the basis of modern Latin American populations. We selected markers on the basis of locus-specific branch length to be informative, well distributed throughout the genome, capable of being genotyped on widely available commercial platforms, and applicable throughout the Americas by minimizing within-continent heterogeneity. We then validated the panel in samples from four admixed populations by comparing ancestry estimates based on the AIMs panel to estimates based on genome-wide association study (GWAS) data. The panel provided balanced discriminatory power among the three ancestral populations and accurate estimates of individual ancestry proportions (R2>0.9 for ancestral components with significant between-subject variance). Finally, we genotyped samples from 18 populations from Latin America using the AIMs panel and estimated variability in ancestry within and between these populations. This panel and its reference genotype information will be useful resources to explore population history of admixture in Latin America and to correct for the potential effects of population stratification in admixed samples in the region.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer

  • Tomlinson, Ian P.
  • Dunlop, Malcolm
  • Campbell, Harry
  • Zanke, Brent W.
  • Gallinger, Steven
  • Hudson, Thomas J.
  • Koessler, Thibaud
  • Pharoah, Paul D. P.
  • Niittymäki, Iina
  • Tuupanen, Sari
  • Aaltonen, Lauri A.
  • Hemminki, Kari
  • Lindblom, Annika
  • Försti, Asta
  • Sieber, Oliver
  • Lipton, Lara
  • Van Wezel, Tom
  • Morreau, Hans
  • Wijnen, Juul
  • Devilee, Peter
  • Matsuda, Kenji
  • Nakamura, Yusuke
  • Castellví Bel, Sergi
  • Ruiz-Ponte, Clara
  • Castells Garangou, Antoni
  • Carracedo Álvarez, Ángel
  • Ho, J.W.
  • Sham, Pak Chung
  • Hofstra, Robert
  • Vodicka, Pavel
  • Brenner, Hermann
  • Hampe, Jochen
  • Schafmayer, Clemens
  • Tepel, Juergen
  • Schreiber, Stefan
  • Völzke, Henry
  • Lerch, Markus M.
  • Schmidt, Christian A.
  • Buch, Stephan
  • Moreno Aguado, Víctor
It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association between CASP8 –652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study

  • Pardini, Barbara
  • Verderio, Paolo
  • Pizzamiglio, Sara
  • Nici, Carmela
  • Maiorana, Maria Valeria
  • Naccarati, Alessio
  • Vodickova, Ludmila
  • Vymetalkova, Veronika
  • Veneroni, Silvia
  • Daidone, Maria Grazia
  • Ravagnani, Fernando
  • Bianchi, Tiziana
  • Bujanda, Luis
  • Carracedo, Angel
  • Castells, Antoni
  • Ruiz-Ponte, Clara
  • Morreau, Hans
  • Howarth, Kimberley
  • Jones, Angela
  • Castellví-Bel, Sergi
  • Li, Li
  • Tomlinson, Ian
  • Van Wezel, Tom
  • Vodicka, Pavel
  • Radice, Paolo
  • Peterlongo, Paolo
Members of the EPICOLON Consortium (Gastrointestinal Oncology Group of the Spanish Gastroenterological Association) are: Hospital 12 de Octubre, Madrid: Juan Diego Morillas (local coordinator), Raquel Muñoz, Marisa Manzano, Francisco Colina, Jose Díaz, Carolina Ibarrola, Guadalupe López, Alberto Ibáñez; Hospital Clínic, Barcelona: Antoni Castells (local coordinator), Virgínia Piñol, Sergi Castellví-Bel, Francesc Balaguer, Victoria Gonzalo, Teresa Ocaña, María Dolores Giráldez, Maria Pellisé, Anna Serradesanferm, Leticia Moreira, Miriam Cuatrecasas, Josep M. Piqué; Hospital Clínico Universitario, Zaragoza: Ángel Lanas (local coordinator), Javier Alcedo, Javier Ortego; Hospital Cristal-Piñor, Complexo Hospitalario de Ourense: Joaquin Cubiella (local coordinator), Ma Soledad Díez, Mercedes Salgado, Eloy Sánchez, Mariano Vega; Parc de Salut Mar, Barcelona: Montserrat Andreu (local coordinator), Anna Abuli, Xavier Bessa, Mar Iglesias, Agustín Seoane, Felipe Bory, Gemma Navarro, Beatriz Bellosillo; Josep Ma Dedeu, Cristina Álvarez, Marc Puigvehí; Hospital San Eloy, Baracaldo and Hospital Donostia, CIBERehd, University of Basque Country, San Sebastián: Luis Bujanda (local coordinator) Ángel Cosme, Inés Gil, Mikel Larzabal, Carlos Placer, María del Mar Ramírez, Elisabeth Hijona, Jose M. Enríquez-Navascués, Jose L. Elosegui; Hospital General Universitario de Alicante: Artemio Payá (EPICOLON I local coordinator), Rodrigo Jover (EPICOLON II local coordinator), Cristina Alenda, Laura Sempere, Nuria Acame, Estefanía Rojas, Lucía Pérez-Carbonell; Hospital General de Granollers: Joaquim Rigau (local coordinator), Ángel Serrano, Anna Giménez; Hospital General de Vic: Joan Saló (local coordinator), Eduard Batiste-Alentorn, Josefina Autonell, Ramon Barniol; Hospital General Universitario de Guadalajara and Fundación para la Formación e Investigación Sanitarias Murcia: Ana María García (local coordinator), Fernando Carballo, Antonio Bienvenido, Eduardo Sanz, Fernando González, Jaime Sánchez, Akiko Ono; Hospital General Universitario de Valencia: Mercedes Latorre (local coordinator), Enrique Medina, Jaime Cuquerella, Pilar Canelles, Miguel Martorell, José Ángel García, Francisco Quiles, Elisa Orti; CHUVI-Hospital Meixoeiro, Vigo: EPICOLON I: Juan Clofent (local coordinator), Jaime Seoane, Antoni Tardío, Eugenia Sanchez. EPICOLON II Ma Luisa de Castro (local coordinator), Antoni Tardío, Juan Clofent, Vicent Hernández; Hospital Universitari Germans Trias i Pujol, Badalona and Section of Digestive Diseases and Nutrition, University of Illinois at Chicago, IL, USA: Xavier Llor (local coordinator), Rosa M. Xicola, Marta Piñol, Mercè Rosinach, Anna Roca, Elisenda Pons, José M. Hernández, Miquel A. Gassull; Hospital Universitari Mútua de Terrassa: Fernando Fernández-Bañares (local coordinator), Josep M. Viver, Antonio Salas, Jorge Espinós, Montserrat Forné, Maria Esteve; Hospital Universitari Arnau de Vilanova, Lleida: Josep M. Reñé (local coordinator), Carmen Piñol, Juan Buenestado, Joan Viñas; Hospital Universitario de Canarias: Enrique Quintero (local coordinator), David Nicolás, Adolfo Parra, Antonio Martín; Hospital Universitario La Fe, Valencia: Lidia Argüello (local coordinator), Vicente Pons, Virginia Pertejo, Teresa Sala; Hospital Sant Pau, Barcelona: Dolors Gonzalez (local coordinator) Eva Roman, Teresa Ramon, Maria Poca, Ma Mar Concepción, Marta Martin, Lourdes Pétriz; Hospital Xeral Cies, Vigo: Daniel Martinez (local coordinator); Fundacion Publica Galega de Medicina Xenomica (FPGMX), CIBERER, Genomic Medicine Group-University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain: Ángel Carracedo (local coordinator), Clara Ruiz-Ponte, Ceres Fernández-Rozadilla, Ma Magdalena Castro; Hospital Universitario Central de Asturias: Sabino Riestra (local coordinator), Luis Rodrigo; Hospital de Galdácano, Vizcaya: Javier Fernández (local coordinator), Jose Luis Cabriada; Fundación Hospital de Calahorra (La Rioja) La Rioja: Luis Carreño (local coordinator), Susana Oquiñena, Federico Bolado; Hospital Royo Villanova, Zaragoza: Elena Peña (local coordinator), José Manuel Blas, Gloria Ceña, Juan José Sebastián; Hospital Universitario Reina Sofía, Córdoba: Antonio Naranjo (local coordinator)., The common −652 6N del variant in the CASP8 promoter (rs3834129) has been described as a putative low-penetrance risk factor for different cancer types. In particular, some studies suggested that the deleted allele (del) was inversely associated with CRC risk while other analyses failed to confirm this. Hence, to better understand the role of this variant in the risk of developing CRC, we performed a multi-centric case-control study. In the study, the variant −652 6N del was genotyped in a total of 6,733 CRC cases and 7,576 controls recruited by six different centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands collaborating to the international consortium COGENT (COlorectal cancer GENeTics). Our analysis indicated that rs3834129 was not associated with CRC risk in the full data set. However, the del allele was under-represented in one set of cases with a family history of CRC (per allele model OR = 0.79, 95% CI = 0.69–0.90) suggesting this allele might be a protective factor versus familial CRC. Since this multi-centric case-control study was performed on a very large sample size, it provided robust clarification of the effect of rs3834129 on the risk of developing CRC in Caucasians., For all cohorts: This work was supported by COST Action BM1206. Spanish cohort: SCB is supported by a contract from the Fondo de Investigación Sanitaria (CP 03-0070 to SCB). Networked Biomedical Research Centre for Hepatic and Digestive Diseases and Centro de Investigación Biomédica en Red de Enfermedades Raras are funded by the Instituto de Salud Carlos III. This work was supported by grants from the Fondo de Investigación Sanitaria/FEDER (08/0024, 08/1276, PS09/02368, 11/00219, 11/00681), Instituto de Salud Carlos III (Acción Transversal de Cáncer), Xunta de Galicia (07PXIB9101209PR), Ministerio de Ciencia e Innovación (SAF2010-19273), Asociación Española contra el Cáncer (Fundación Científica y Junta de Barcelona), Fundació Olga Torres (SCB and CRP), FP7 CHIBCHA Consortium (SCB and A. Carracedo). American cohort: Kentucky Colon Cancer Genetic Epidemiology Study is supported by National Institutes of Health grant R01CA136726 to LL. English cohort: Core funding to the Wellcome Trust Centre for Human Genetics was provided by the Wellcome Trust (090532/Z/09/Z). Czech cohort: Grant agency of the Czech Republic (GACR) [CZ:GACR:GA P304/10/1286 and P304/12/1585] and by Prvouk-P27/LF1/1 from Ministry of Education, Youth and Sport, Czech Republic (First Medical Faculty, Charles University, Prague, Czech Republic as a recipient). Dutch cohort: Dutch Cancer Society, grant KWF-UL-2010-4656.